Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis

Cancer Chemotherapy and Pharmacology, 01/28/2013

The study aims to gain a better understanding of the overall incidence and risk of hypertension in cancer patients who receive pazopanib and to compare the differences in incidence among sorafenib, sunitinib, and pazopanib. The use of pazopanib is associated with a significantly increased risk of developing hypertension. Close monitoring and appropriate managements are recommended during the therapy. Future studies are still needed to investigate the risk reduction and possible use of pazopanib in selected patients.

Print Article Summary Cat 2 CME Report